The approved pills changed the maths
Two oral GLP-1s were approved either side of the new year, both starting at $149 a month. That undercuts a large part of the compounded market.
Updated 2026-09-18
The biggest competitive threat to the compounded market in 2026 did not come from another compounder. It came from Novo Nordisk and Eli Lilly pricing approved pills at $149.
Both start at $149 a month self-pay. That is more than the cheapest compounded programmes — Ozari Health is $86 and Trimi is $125 — but it is less than the majority of what we track, and it buys a product the FDA has actually reviewed.
What it does to the board
Every listing above $149 now competes against an approved product at the same price or less. The desk expects that to squeeze the mid-market hardest — the programmes charging $278 to $449 for compounded injections have the least defensible position on the board as of this year.
Wegovy pill (oral semaglutide)
Approved late December 2025, launched in the US on 5 January 2026. The first oral GLP-1 approved for weight management — the same active ingredient as the Wegovy injection, taken as a daily tablet.
Self-pay from $149/month for the 1.5 mg starting dose. The 4 mg dose was offered at $149/month through 15 April 2026 and $199/month after, with the highest doses around $299/month.
Available through LillyDirect-style manufacturer channels and telehealth partners including Ro, GoodRx Care Direct and Walgreens.
How they compare with what we normally cover
| Option | From | Form | FDA-approved? |
|---|---|---|---|
| Wegovy pill (oral semaglutide) | $149/mo | Daily tablet | Yes |
| Foundayo (orforglipron) | $149/mo | Daily tablet | Yes |
| Cheapest compounded semaglutide (Ozari Health) | $86/mo | Weekly injection | No |
| Cheapest compounded tirzepatide (Trimi) | $125/mo | Weekly injection | No |
| Typical compounded programme | $189–$449/mo | Weekly injection | No |
| Wegovy injection, self-pay | $199 then $349/mo | Weekly injection | Yes |
Read this bit. What this does not mean. A pill is not automatically better than an injection. Oral semaglutide has strict instructions about taking it on an empty stomach with a small sip of water and waiting before eating — get that wrong and it underperforms. And the trial weight-loss figures for injectable tirzepatide remain the highest of any of these options.
Who should actually consider switching
- Anyone paying more than about $200 a month for a compounded injection. You are now paying a premium for a non-approved product, which is a strange place to be.
- Anyone who never wanted to inject. This is the obvious one — a genuine approved alternative now exists at a sane price.
- Anyone uneasy about the compounding rules. The 2026 regulatory direction is not friendly to compounded GLP-1s; see is compounded still legal.
- Medicare beneficiaries. From July 2026 you may be able to get an approved GLP-1 for $50 a month — see the Medicare programme.
More from the desk
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- The compounding rules
Cheap GLP-1s exist because of compounding. The FDA moved against it again in April. What that means for the board.
- Tirzepatide vs semaglutide
A head-to-head trial settled the results question. The price question goes the other way.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure